alpelisib

The SOLAR-1 trial: alpelisib prolongs progression free survival in PIK3CA-mutated, HR-positive, HER2-negative breast cancer patients

1. Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer patients who have a mutated phosphatidylinositol 3-kinase (PIK3) with the PIK3 inhibitor alpelisib, in addition to fulvestrant, increased progression free survival compared to treatment with fulvestrant alone. 2. The most common severe adverse effects in Czytaj więcej…

anastrazole

#VisualAbstract: Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer

1. A randomized control trial of patients with hormone receptor-positive metastatic breast cancer compared survival outcomes between patients who received combined anastrozole and fulvestrant therapy versus those receiving anastrozole alone, concluded that the combined therapy led to improved disease progression-free survival and overall survival rates. 2. There were no significant Czytaj więcej…